Analysis of five bacterial markers present in the gut microbiome — the community of microbes living in the gut — may help in diagnosing myasthenia gravis (MG) in children, according to a Chinese study. The study, “Metagenome-wide association study of gut microbiome revealed potential microbial marker…
AllianceRx Walgreens Prime, a specialty and home delivery pharmacy, is partnering with TailorMed, a healthcare technology company, to help lower out-of-pocket prescription costs for specialty pharmacy patients. Medications attained through specialty pharmacies are those used to treat rare and chronic conditions in the U.S., and are often extremely costly. For…
Patients who start experiencing symptoms of myasthenia gravis (MG) after age 65 have an overall good prognosis and response to immunosuppressive treatments, according to a recent Canadian study. In addition, the presence of other medical conditions, or comorbidities, had no effect on the severity of MG symptoms or on…
Ultomiris (ravulizumab-cwvz) rapidly and sustainably eased symptom severity in adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 trial. Alexion Pharmaceuticals, the therapy’s developer, now plans to submit regulatory applications requesting approval of Ultomiris for gMG in the U.S., Europe, and Japan, later…
Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…
People with generalized myasthenia gravis (MG) who have other diseases, or comorbidities, have a worse prognosis and are less likely to go into remission after thymus removal than those without other medical conditions. Those were the findings of a recent study that followed patients for about nine years after…
Harbour BioMed’s investigational therapy batoclimab (HBM9161) safely and rapidly eases symptoms and lowers the levels of harmful antibodies in adults with moderate-to-severe generalized myasthenia gravis (gMG), according to top-line data from a Phase 2 clinical trial in China. “The strong evidence generated from this study is quite exciting…
Women with myasthenia gravis (MG) given standard treatment improve significantly less in both objective and patient-reported outcome measures than do men, a study in Denmark with nearly five years of follow-up data reported. Notably, this sex difference was independent of age, disease duration, simultaneous health conditions (comorbidities), and prior…
A very rare case of a myasthenia gravis (MG) crisis caused by the Moderna COVID-19 vaccine was described recently by researchers at St. Joseph’s Regional Medical Center in Paterson, New Jersey. “Although numerous studies have observed the relationship between active COVID infections and MG exacerbations, no known studies or…
Patient dosing has begun in a Phase 1/2a clinical trial of NMD670, an investigational oral therapy by NMD Pharma aiming to improve motor abilities and quality of life for people with myasthenia gravis (MG). “We are pleased to announce the dosing of the first myasthenia gravis patient today…
Get regular updates to your inbox.